Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PHGDH | O43175 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19331846 | 0.85 | ABCB11 (0.57) | CCR2GPR35ABCB11KDM4EPOLB | |
| SCHEMBL19332364 | 0.84 | KRAS (0.55) | KDM4EPKMPHGDHALDH1A1HPGD | |
| SCHEMBL703225 | 0.83 | ALDH1A1 (0.50) | KDM4EPOLBPKMALDH1A1HPGD | |
| SCHEMBL6303492 | 0.80 | CCR2 (0.74) | CCR2ABCB11 | |
| SCHEMBL19330994 | 0.80 | PHGDH (0.60) | GPR35ABCB11KDM4EPHGDHALDH1A1 | |
| SCHEMBL30040722 | 0.80 | PHGDH (0.60) | GPR35ABCB11KDM4EPHGDHALDH1A1 | |
| SCHEMBL31332410 | 0.77 | NPC1 (0.46) | CCR2ABCB11PHGDHMAPT | |
| SCHEMBL31332415 | 0.77 | NPC1 (0.46) | CCR2ABCB11PHGDHMAPT | |
| SCHEMBL699618 | 0.75 | PHGDH (0.46) | POLBPHGDHHPGDMEN1MAPT | |
| SCHEMBL700700 | 0.74 | CCR2 (0.65) | CCR2GPR35ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2367817-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065310-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065310-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | CCR2 4191/4885GPR35 1008/4885ABCB11 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.